- Trial phase
- Phase 3
- Time to market
- At least 3-5 years away if Phase 3 trials succeed. The GOLSEEK-1 primary completion is August 2027, followed by data analysis, regulatory filing (likely 2028), and FDA review (2028-2029).
- Why 6/10
- The next hard catalyst is the GOLSEEK-1 Phase 3 primary completion/readout expected around August 9, 2027 (about 9.5 months from today). This is a pivotal readout on a meaningful pipeline asset, but BMY is a diversified mega-cap pharma with many approved products and pipeline programs, so this single drug does not drive most of the company's valuation.
The next hard catalyst is the GOLSEEK-1 Phase 3 topline readout for golcadomide + R-CHOP in high-risk large B-cell lymphoma, with primary completion estimated around August 9, 2027. A positive readout would support a future NDA filing and position golcadomide as a potential first-in-class oral CELMoD for lymphoma. A negative or mixed result would likely end the program. For BMY, a diversified mega-cap, the stock impact would be modest relative to a single-asset biotech.
Price Chart
Executive Summary
Golcadomide is Bristol Myers Squibb's (BMY) investigational oral CELMoD agent in Phase 3 testing for B-cell non-Hodgkin lymphomas (high-risk large B-cell lymphoma and relapsed/refractory follicular lymphoma). It is not yet FDA approved and no NDA has been filed. The nearest hard catalyst is the GOLSEEK-1 Phase 3 primary completion/readout expected around August 2027. BMY is a mega-cap pharma with dozens of marketed products and a deep pipeline, so golcadomide is a meaningful but not company-defining asset. Two sibling CELMoDs from BMS (iberdomide and mezigdomide) were both FDA-approved in 2026 for multiple myeloma, validating the platform but not this specific lymphoma indication.
How It Works
Golcadomide is an oral pill that works as a 'molecular glue' inside cells. It binds to a protein called cereblon, which then marks two cancer-promoting proteins (Ikaros and Aiolos) for destruction by the cell's garbage-disposal system. This kills lymphoma cells directly and also boosts the immune system's ability to fight the cancer. It is designed to concentrate in lymph tissues where lymphoma grows.
Trial Status
Two Phase 3 trials are ongoing: GOLSEEK-1 (NCT06356129) evaluating golcadomide + R-CHOP vs placebo + R-CHOP in ~850 patients with previously untreated high-risk large B-cell lymphoma (enrollment complete, active not recruiting, primary completion moved to August 9, 2027); and GOLSEEK-4 (NCT06911502) evaluating golcadomide + rituximab vs investigator's choice in relapsed/refractory follicular lymphoma (currently recruiting). Phase 1/2 data presented at ASH 2025 and ASCO 2026 showed promising efficacy with durable responses and manageable safety.
The Two-Sided Case
Upcoming Catalysts
- GOLSEEK-1 Phase 3 primary completion/readout for golcadomide + R-CHOP in high-risk large B-cell lymphoma, estimated around August 9, 2027
- GOLSEEK-4 Phase 3 enrollment updates and potential interim analyses for golcadomide + rituximab in relapsed/refractory follicular lymphoma
- Additional data presentations at upcoming medical conferences (ASH 2026, ASCO 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report